bupropion sustained-release / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 27 Diseases   22 Trials   22 Trials   341 News 


1234567»
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Trial completion date, Trial primary completion date:  CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) -  Oct 4, 2024   
    P4,  N=120, Recruiting, 
    Follow-up studies are needed as these decreases were not identified throughout the full study period or at termination. Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  bupropion sustained-release / Generic mfg., bupropion / Generic mfg.
    Journal:  Sustained release of 3D printed bupropion hydrochloride tablets bearing Braille imprints for the visually impaired. (Pubmed Central) -  Sep 1, 2024   
    The selection of poly(ethylene glycol) (PEG)-diacrylate (PEGDA) of different molecular weights and the presence of surfactants or solubilizers disrupted the resin photopolymerization, thus controlling the BUP dissolution rates. A small batch scale-up study demonstrated the capacity of LCD to print rapidly a notable number of tablets within 24?min.
  • ||||||||||  zonisamide / Generic mfg.
    Trial completion date, Trial primary completion date:  The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) -  Aug 15, 2024   
    P3,  N=180, Recruiting, 
    A small batch scale-up study demonstrated the capacity of LCD to print rapidly a notable number of tablets within 24?min. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
  • ||||||||||  Review, Journal:  The Black Book of Psychotropic Dosing and Monitoring. (Pubmed Central) -  Jul 12, 2024   
    While acetylcholinesterase inhibitors and memantine have been available for decades, these drugs modestly improve cognition in Alzheimer's disease patients and do not alter the progressive course of the illness...While it remains to be seen how useful these new agents will be in clinical practice, they do represent an approach to treating neuropsychiatric disorders that are a notable departure from the pharmacotherapy of the past half century. It seems likely that some patients who have not been able to respond to or tolerate traditional pharmacotherapy will find hope in these new medications.
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion:  Varenicline and Bupropion for Alcohol Use Disorder (clinicaltrials.gov) -  Jun 7, 2024   
    P2,  N=388, Completed, 
    It seems likely that some patients who have not been able to respond to or tolerate traditional pharmacotherapy will find hope in these new medications. Recruiting --> Completed
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Trial completion date, Trial primary completion date:  CPT-SMART for Treatment of PTSD and Cigarette Smoking (clinicaltrials.gov) -  Apr 19, 2024   
    P4,  N=120, Recruiting, 
    Recruiting --> Completed Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Apr 2024 --> Sep 2024
  • ||||||||||  Xatmep (methotrexate oral solution) / Azurity Pharma, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka, Daiichi Sankyo
    Trial completion, Enrollment change:  Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants (clinicaltrials.gov) -  Apr 9, 2024   
    P=N/A,  N=39, Completed, 
    Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Apr 2024 --> Sep 2024 Recruiting --> Completed | N=304 --> 39
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Trial termination, HEOR:  Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) -  Feb 15, 2024   
    P=N/A,  N=1037352, Terminated, 
    Trial completion date: Mar 2026 --> Jul 2026 Completed --> Terminated; Per PI, this study is not a clinical trial and was inadvertently entered in the system
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion date, Trial primary completion date:  Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (clinicaltrials.gov) -  Nov 1, 2023   
    P=N/A,  N=3200, Recruiting, 
    Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: May 2023 --> Feb 2024 Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Jan 2024 --> Nov 2024
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya (clinicaltrials.gov) -  Aug 15, 2023   
    P3,  N=300, Completed, 
    Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Jan 2024 --> Nov 2024 Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2023 | Trial primary completion date: Dec 2024 --> Jul 2023
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Embedding Comprehensive Smoking Cessation Programs Into Community Clinics (clinicaltrials.gov) -  Aug 14, 2023   
    P=N/A,  N=406, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2023 | Trial primary completion date: Dec 2024 --> Jul 2023 Recruiting --> Completed | N=1200 --> 406 | Trial completion date: Jun 2023 --> Nov 2022 | Trial primary completion date: Jun 2023 --> Nov 2022
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Enrollment open:  Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (clinicaltrials.gov) -  Jun 18, 2023   
    P4,  N=580, Recruiting, 
    Recruiting --> Completed | N=1200 --> 406 | Trial completion date: Jun 2023 --> Nov 2022 | Trial primary completion date: Jun 2023 --> Nov 2022 Not yet recruiting --> Recruiting
  • ||||||||||  bupropion sustained-release / Generic mfg., bupropion / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  (KISV): Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment (clinicaltrials.gov) -  Mar 2, 2023   
    P3,  N=500, Recruiting, 
    ClinicalTrials.gov Identifier: NCT02111798. Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Aug 2025 --> Nov 2025
  • ||||||||||  Chantix (varenicline) / Pfizer
    Ascertaining Evidence and Strategies for Medical Treatment of Adolescents With Substance Use Disorders (SUD) (Room 153, Moscone South Room Level: Upper Mezzanine) -  Jan 29, 2023 - Abstract #APA2023APA_286;    
    This session is intended to examine, identify, and evaluate the various means of psychotropic medical management of SUD in the adolescent population to improve the clinical care and medical management of this highly vulnerable population. While management is multidisciplinary and complex, both FDA-approved and off-label uses of MAT show great promise for this demographic and act in the continued battle against the opioid epidemic, aiding in apt management, reduced stigma, improved quality of life, and increased societal integration of these adolescents and young adults.Learning Objectives Objective One: To identify diagnostic criteria and recognize presentations of substance use disorders (SUD) in adolescents, including opioid use disorder (OUD), alcohol use disorder (AUD), and cannabis use disorder Objective Two: To categorize and assess varying evidence, efficacy, risks, and indications of MAT in adolescents, including NAC, naltrexone, disulfiram, acamprosate, NRT, buproprion-S Objective Three: To elucidate and establish evidence-based practices for medication-assisted management of adolescents with substance use disorders (SUD) Objective Four: Objective Five:
  • ||||||||||  Auvelity (bupropion/dextromethorphan) / Axsome Therap
    Journal:  Dextromethorphan/bupropion (Auvelity) for depression. (Pubmed Central) -  Dec 22, 2022   
    While management is multidisciplinary and complex, both FDA-approved and off-label uses of MAT show great promise for this demographic and act in the continued battle against the opioid epidemic, aiding in apt management, reduced stigma, improved quality of life, and increased societal integration of these adolescents and young adults.Learning Objectives Objective One: To identify diagnostic criteria and recognize presentations of substance use disorders (SUD) in adolescents, including opioid use disorder (OUD), alcohol use disorder (AUD), and cannabis use disorder Objective Two: To categorize and assess varying evidence, efficacy, risks, and indications of MAT in adolescents, including NAC, naltrexone, disulfiram, acamprosate, NRT, buproprion-S Objective Three: To elucidate and establish evidence-based practices for medication-assisted management of adolescents with substance use disorders (SUD) Objective Four: Objective Five: No abstract available
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Integrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, Kenya (clinicaltrials.gov) -  Oct 6, 2022   
    P4,  N=580, Not yet recruiting, 
    Our findings suggest that, during a period when e-cigarettes are widely available, cigarette tax increases remain effective in increasing use of these medications, but e-cigarette taxes do not increase use of these medications. Trial completion date: Aug 2026 --> Nov 2024 | Initiation date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2023 --> Nov 2024
  • ||||||||||  zonisamide / Generic mfg.
    Trial completion date, Trial primary completion date:  The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (clinicaltrials.gov) -  Aug 23, 2022   
    P3,  N=180, Recruiting, 
    Trial completion date: Aug 2026 --> Nov 2024 | Initiation date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2023 --> Nov 2024 Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Dec 2022 --> May 2023
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date:  PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness (clinicaltrials.gov) -  Aug 11, 2022   
    P4,  N=120, Recruiting, 
    Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Dec 2022 --> May 2023 N=60 --> 120 | Trial completion date: Jul 2022 --> Jul 2025 | Trial primary completion date: Jul 2022 --> Jul 2025
  • ||||||||||  aripiprazole / Generic mfg., bupropion sustained-release / Generic mfg., fluoxetine / Generic mfg.
    Serotonin Syndrome in a 50-Year-Old Female: A Case Report () -  May 5, 2022 - Abstract #APA2022APA_635;    
    She was on several psychotropic medications: bupropion SR 200 mg twice daily, fluoxetine 40 mg twice daily, lamotrigine 200 mg twice daily, and buspirone 15 mg twice daily...The patient’s bupropion SR dosage was decreased to 150 mg twice daily and aripiprazole 5 mg daily was started for the hallucinations...While the true incidence of SS is unknown, it is commonly seen in patients prescribed SSRIs. Prevention and recognition of this potentially life-threatening syndrome should be at the forefront of anyone prescribing serotonergic agents, especially psychiatrists.
  • ||||||||||  zonisamide / Generic mfg.
    Trial completion:  BuZonE: Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes (clinicaltrials.gov) -  Mar 29, 2022   
    P3,  N=26, Completed, 
    Prevention and recognition of this potentially life-threatening syndrome should be at the forefront of anyone prescribing serotonergic agents, especially psychiatrists. Active, not recruiting --> Completed
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion, Trial completion date:  Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) -  Mar 10, 2022   
    P3,  N=392, Completed, 
    For a subset of patients who chose to add BUP-SR to their behavioral therapy, fatigue improves further but not to a statistically significant effect compared to behavioral therapy alone. Active, not recruiting --> Completed | Trial completion date: May 2023 --> Jan 2022
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial primary completion date:  Individualizing Pharmacotherapy for African American Smokers (clinicaltrials.gov) -  Mar 9, 2022   
    P3,  N=392, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2023 --> Jan 2022 Trial primary completion date: Apr 2022 --> Jan 2022
  • ||||||||||  Chantix (varenicline) / Pfizer
    Phase classification:  Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (clinicaltrials.gov) -  Feb 16, 2022   
    P4,  N=12, Completed, 
    Further work on the importance of sex as a biological variable and how the complex interoceptive stimulus effects of nicotine can vary with training histories is needed. Phase classification: P=N/A --> P4
  • ||||||||||  bupropion sustained-release / Generic mfg.
    Zyban (Twitter) -  Feb 11, 2022   
  • ||||||||||  Chantix (varenicline) / Pfizer
    Trial completion, Enrollment change, Trial primary completion date:  Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) (clinicaltrials.gov) -  Jan 19, 2022   
    P=N/A,  N=8, Completed, 
    Phase classification: P=N/A --> P4 Recruiting --> Completed | N=15 --> 8 | Trial primary completion date: Jan 2022 --> Jul 2021